Single dose prostate radiotherapy - a step too far?

Alison C Tree^{1

2}, Nicholas J van As^{3

4}

Affiliations

Comment

Alison C Tree et al. Nat Rev Urol. 2021 Aug.

. 2021 Aug;18(8):445-446.

doi: 10.1038/s41585-021-00468-y.

Alison C Tree^{1

2}, Nicholas J van As^{3

4}

No abstract available

Comment on

Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial.
Greco C, Pares O, Pimentel N, Louro V, Santiago I, Vieira S, Stroom J, Mateus D, Soares A, Marques J, Freitas E, Coelho G, Seixas M, Lopez-Beltran A, Fuks Z. Greco C, et al. JAMA Oncol. 2021 May 1;7(5):700-708. doi: 10.1001/jamaoncol.2021.0039. JAMA Oncol. 2021. PMID: 33704378 Free PMC article. Clinical Trial.

1. Dearnaley, D. et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 17, 1047–1060 (2016). - DOI
1. Brand, D. H. et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity results from an international, randomised open-label, phase 3, non-inferiority trial. Lancet Oncol. 20, 1531–1543 (2019). - DOI
1. Widmark, A. et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394, 385–395 (2019). - DOI
1. Greco, C. et al. Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: results from the PROSINT phase 2 randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2021.0039 (2021). - DOI - PubMed
1. Meier, R. M. et al. Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int. J. Radiat. Oncol. Biol. Phys. 102, 296–303 (2018). - DOI